GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

OBI Pharma 4174.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

53.40

+9.99%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 58.6m

FY2016FY2025

Net income

−TWD 2.05bn

FY2016FY2025

Free cash flow

−TWD 2.07bn

FY2016FY2025

Shareholders' equity

TWD 1.89bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueTWD 58.6mTWD 62.7mTWD 41.5mTWD 4.7mTWD 18.8mTWD 140.9mTWD 872,000TWD 13.3mTWD 376,000TWD 92.4m
Research and developmentTWD 1.73bnTWD 1.97bnTWD 1.70bnTWD 1.77bnTWD 1.45bnTWD 1.31bnTWD 1.18bnTWD 1.13bnTWD 848.7mTWD 859.5m
Operating income−TWD 2.17bn−TWD 2.37bn−TWD 2.09bn−TWD 1.91bn−TWD 1.74bn−TWD 1.49bn−TWD 1.49bn−TWD 1.43bn−TWD 1.38bn−TWD 1.11bn
Net income−TWD 2.05bn−TWD 2.31bn−TWD 1.27bn−TWD 1.90bn−TWD 1.72bn−TWD 1.49bn−TWD 1.44bn−TWD 1.22bn−TWD 1.38bn−TWD 1.11bn
Diluted earnings per share-15.60-10.08-5.53-8.29-8.55-7.91-7.67-7.00-8.00-6.47

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsTWD 3.42bnTWD 5.65bnTWD 5.60bnTWD 6.63bnTWD 4.49bnTWD 5.34bnTWD 5.66bnTWD 4.71bnTWD 5.19bnTWD 6.33bn
Cash and short-term investments——TWD 2.78bnTWD 4.77bnTWD 2.65bnTWD 3.72bnTWD 4.55bnTWD 3.66bnTWD 4.58bnTWD 3.77bn
Total liabilitiesTWD 696.1mTWD 833.4mTWD 650.4mTWD 497.6mTWD 615.9mTWD 502.1mTWD 459.1mTWD 236.0mTWD 129.7mTWD 167.3m
DebtTWD 29.5mTWD 504.6mTWD 501.1mTWD 247.1mTWD 293.0mTWD 246.0mTWD 276.2mTWD 62.0mTWD 71.0mTWD 80.0m
Shareholders' equityTWD 1.89bnTWD 3.81bnTWD 3.81bnTWD 4.63bnTWD 2.72bnTWD 4.23bnTWD 5.10bnTWD 4.35bnTWD 5.06bnTWD 6.16bn
Shares outstanding132m229m229m229m201m188m188m175m172m172m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−TWD 2.02bn−TWD 1.83bn−TWD 1.65bn−TWD 1.62bn−TWD 1.06bn−TWD 1.61bn−TWD 1.05bn−TWD 864.3m−TWD 1.11bn−TWD 840.1m
Capital spending−TWD 48.3m−TWD 119.6m−TWD 108.2m−TWD 300.6m−TWD 245.2m−TWD 185.6m−TWD 51.6m−TWD 20.8m−TWD 152.4m−TWD 183.4m
Free cash flow−TWD 2.07bn−TWD 1.95bn−TWD 1.76bn−TWD 1.92bn−TWD 1.31bn−TWD 1.80bn−TWD 1.10bn−TWD 885.1m−TWD 1.26bn−TWD 1.02bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 15.3mTWD 5.6mTWD 20.8mTWD 10.5mTWD 12.8mTWD 14.5mTWD 11.5mTWD 23.0m
Operating income−TWD 265.8m−TWD 454.4m−TWD 480.2m−TWD 496.6m−TWD 680.5m−TWD 511.4m−TWD 721.7m−TWD 534.1m
Net income−TWD 197.6m−TWD 440.5m−TWD 419.5m−TWD 468.3m−TWD 653.5m−TWD 511.5m−TWD 727.8m−TWD 519.3m
Diluted earnings per share-1.50-3.35-3.19-3.56-4.97-3.89-3.17-2.27
Cash from operations−TWD 290.0m−TWD 351.0m−TWD 479.0m−TWD 407.0m−TWD 470.0m−TWD 662.0m−TWD 402.0m−TWD 439.0m
Capital spending−TWD 2.0m−TWD 6.0m−TWD 9.0m−TWD 4.0m−TWD 14.0m−TWD 19.0m−TWD 11.0m−TWD 20.0m
Free cash flow−TWD 292.0m−TWD 357.0m−TWD 488.0m−TWD 411.0m−TWD 484.0m−TWD 681.0m−TWD 413.0m−TWD 459.0m
Total assetsTWD 2.69bnTWD 2.86bnTWD 3.42bnTWD 3.83bnTWD 4.32bnTWD 4.89bnTWD 5.65bnTWD 4.00bn
Debt—TWD 11.3mTWD 29.5mTWD 47.5mTWD 65.5mTWD 39.7mTWD 48.2mTWD 56.7m
Shareholders' equityTWD 1.49bnTWD 1.47bnTWD 1.89bnTWD 2.19bnTWD 2.64bnTWD 3.31bnTWD 3.81bnTWD 2.36bn

Financial ratios

Data as of 15 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin-3835.0%-3965.6%-3050.9%-40609.3%-9260.9%-1057.2%—
Net margin-3504.6%-3685.5%-3046.9%-40316.8%-9151.3%-1057.5%—
Return on equity-108.7%-60.6%-33.3%-41.0%-63.3%-35.2%—
Return on assets-60.0%-40.9%-22.6%-28.6%-38.3%-27.9%—
Free cash flow yield—-12.5%-11.3%-9.6%-6.8%-12.6%-8.9%
Revenue growth-6.5%50.9%782.0%-74.9%-86.7%16056.7%—
Earnings growth-11.1%82.5%-33.3%10.6%15.3%3.5%—
Current ratio4.51x8.34x19.92x22.76x8.72x15.67x—
Debt to equity0.02x0.01x0.02x0.02x0.03x0.02x—
Equity ratio55.2%67.5%67.9%69.8%60.5%79.2%—
Interest coverage-171.05x-233.36x-159.71x-479.47x-457.73x-356.00x—
R&D as a share of sales2952.3%3140.6%4084.4%37632.3%7722.1%929.7%—
Buybacks as a share of market value—-0.1%0.0%-14.0%-6.7%-0.4%-7.5%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue131.7%-16.1%—
Operating income4.3%7.8%7.4%
Net income2.6%6.6%8.1%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-3744.5%-5100.0%-3597.9%—
Net margin-3598.1%-4494.1%-3281.4%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-3.5-11.6-25.0-16.6-26.3-34.6-33.9-43.6-36.7-86.0
Price to sales121.3427.9———365.8————

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1000-to-500 reverse split · 27 Jan 2026
  • 1000-to-500 reverse split · 26 Jan 2026
  • 1000-to-500 reverse split · 15 Jan 2026
  • 1000-to-500 reverse split · 14 Jan 2026

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.